<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82781">
  <stage>Registered</stage>
  <submitdate>29/04/2008</submitdate>
  <approvaldate>12/05/2008</approvaldate>
  <actrnumber>ACTRN12608000243314</actrnumber>
  <trial_identification>
    <studytitle>IBCSG 35-07 / BIG 1-07 : Study of Letrozole Extension (SOLE).  Letrozole in Preventing the Return of Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer.</studytitle>
    <scientifictitle>Postmenopausal women with hormone-receptor positive, node positive early breast cancer will have treatment with continuous letrozole compared with treatment with intermittent letrozole after 4 to 6 years of prior adjuvant endocrine treatment to see which is better at preventing the return of cancer.</scientifictitle>
    <utrn />
    <trialacronym>SOLE</trialacronym>
    <secondaryid>NCT00553410 (ClinicalTrials.gov)</secondaryid>
    <secondaryid>EUDRACT-2007-001370-88 (European Commission - European Clinical Trials Database)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endocrine Responsive Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study is designed to compare the following treament arms: A) Continuous oral letrozole 2.5mg daily for 5 years, and B) Intermittent oral letrozole 2.5mg daily for the first 9 months of years 1 through 4, followed by 12 months in year 5.</interventions>
    <comparator>Continuous oral letrozole 2.5mg given daily for 5 years</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease-free survival (DFS).  DFS is defined as the time from randomisation to local, regional, or distant relapse, contralateral breast cancer, appearance of a second (non-breast) malignancy, or death from any cause, whichever occurs first.</outcome>
      <timepoint>Two interim and one final analyses are planned. The target number of events for the final analysis is 647, and interim analyses are planned after 40% and 70% information (259 and 453 events observed respectively).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival (OS).  OS is defined as the time from randomisation to death from any cause.</outcome>
      <timepoint>The target number of events for the final analysis is 647, and interim analyses are planned after 40% and 70% information (259 and 453 events observed respectively).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Distant disease-free survival (DDFS).  DDFS is defined as the time from randomisation to any recurrent or metastatic disease in distant sites (i.e., other than the local mastectomy scar/chest wall/skin, the ipsilateral breast in case of breast conservation, or the ipsilateral axilla and internal mammary lymph nodes), second (non-breast) malignancy, or death from any cause, whichever occurs first.</outcome>
      <timepoint>Two interim and one final analyses are planned. The target number of events for the final analysis is 647, and interim analyses are planned after 40% and 70% information (259 and 453 events observed respectively).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Breast Cancer Free Interval (BCFI).  BCFI is defined as the time from randomisation to local (including recurrence restricted to the breast after breast conserving treatment), regional, or distant relapse, or contralateral breast cancer.  Second (non-breast) malignancies are ignored and deaths without cancer event are censored at the time of death as a competing event.</outcome>
      <timepoint>Two interim and one final analyses are planned. The target number of events for the final analysis is 647, and interim analyses are planned after 40% and 70% information (259 and 453 events observed respectively).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sites of first DFS failure</outcome>
      <timepoint>Two interim and one final analyses are planned. The target number of events for the final analysis is 647, and interim analyses are planned after 40% and 70% information (259 and 453 events observed respectively).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Second (non-breast) malignancies</outcome>
      <timepoint>Two interim and one final analyses are planned. The target number of events for the final analysis is 647, and interim analyses are planned after 40% and 70% information (259 and 453 events observed respectively).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Deaths without prior cancer event</outcome>
      <timepoint>Two interim and one final analyses are planned. The target number of events for the final analysis is 647, and interim analyses are planned after 40% and 70% information (259 and 453 events observed respectively).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of targeted adverse events</outcome>
      <timepoint>Two interim and one final analyses are planned. The target number of events for the final analysis is 647, and interim analyses are planned after 40% and 70% information (259 and 453 events observed respectively).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients must be postmenopausal.  Have had operable, non-inflammatory breast cancer at diagnosis.  Must be clinically disease-free at randomisation.  Have had ER and/or PgR positive tumours after primary surgery and before commencement of prior endocrine therapy.  Following primary surgery, patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes, but not supraclavicular nodes.    Must have had proper local treatment including surgery with/without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease.  Patients must have clinically adequate hepatic function.  Patients must have completed 4 to 6 years of prior adjuvant endocrine therapy with selective estrogen receptor modulators (SERM(s)), aromatase inhibitors(AI(s)), or a sequential combination of both (neoadjuvant endocrine therapy should not be included).  Patients must have stopped prior endocrine SERM/AI therapy, and must be randomised within 12 months of the last dose of prior endocrine SERM/AI therapy.  Patients may have received any type of prior adjuvant therapy, including but not limited to neoadjuvant chemotherapy, neoadjuvant endocrine therapy, adjuvant chemotherapy, trastuzumab, ovarian ablation, GnRH analogues, lapatinib.  Pathology material from the primary tumour must be available for submission for central review.  Written Informed Consent, and written consent to pathology material submission.  Must be accessible for follow-up.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Evidence of recurrent disease or distant metastatic disease at any time prior to randomisation.  Patients who have had bilateral breast cancer.  Bone fracture due to osteoporosis at any time during the 4-6 years of prior SERM/AI therapy.  Previous or concomitant malignancy EXCEPT adequately treated: basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, contra- or ipsilateral in situ breast carcinoma.  Other non-malignant systemic diseases (cardiovascular, renal, lung, etc.) that would prevent prolonged follow-up.  Psychiatric, addictive, or any disorder which compromises compliance with protocol rquirements.  Concurrent hormone replacement therapy, bisphosphonates (except for treatment of bone loss), or any investigational agent at randomisation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone/fax/computer</concealment>
    <sequence>Computer generated stratified blocks.  Patients will be stratified according to the institution of recruitment and prior adjuvant endocrine therapy (AI(s) &amp; SERM(s)): AI alone, SERM alone, both SERM and AI.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/06/2008</anticipatedstartdate>
    <actualstartdate>1/09/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>17/08/2012</actualenddate>
    <samplesize>4800</samplesize>
    <actualsamplesize>4884</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,QLD,WA,TAS</recruitmentstate>
    <postcode>2350</postcode>
    <postcode>2298</postcode>
    <postcode>2139</postcode>
    <postcode>2444</postcode>
    <postcode>2031</postcode>
    <postcode>2348</postcode>
    <postcode>2485</postcode>
    <postcode>7250</postcode>
    <postcode>7000</postcode>
    <postcode>3084</postcode>
    <postcode>3128</postcode>
    <postcode>3135</postcode>
    <postcode>3002</postcode>
    <postcode>6000</postcode>
    <postcode>6008</postcode>
    <postcode>6099</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Waikato</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharma AG</primarysponsorname>
    <primarysponsoraddress>Lichtstrasse 35
4056 Basel</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>IBCSG (International Breast Cancer Study Group)</fundingname>
      <fundingaddress>IBCSG Coordinating Center
Effingerstrasse 40
CH- 3008 BERN</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>BIG (Breast International Group)</fundingname>
      <fundingaddress>c/o Institut Jules Bordet 
121 Blvd de Waterloo, 7th floor 
B-1000 Brussels</fundingaddress>
      <fundingcountry>Belgium</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to determine whether intermittent treatment with the drug letrozole is more effective than continuous letrozole treatment in preventing the return of cancer in postmenopausal women with endocrine responsive breast cancer who have undergone 4 to 6 years of prior endocrine therapy.

Who is it for? 
You may be eligible join this study if you are a postmenopausal woman who has had operable, non-inflammatory breast cancer but are now clinically disease-free. You must have completed 4 to 6 years of prior endocrine therapy with selective estrogen receptor modulators (SERM(s)), aromatase inhibitors (AI(s)), or a combination of both.

Trial details
Participants in this trial will be randomly (by chance) allocated to one of two groups. One group will take one 2.5mg letrozole tablet per day for 5 years. Participants in the other group will take letrozole 2.5mg tablets intermittently, i.e. once daily for the first 9 months of years 1 through 4, followed by 12 months in year 5.

Participants will be regularly assessed over the duration of the trial to determine whether continuous or intermittent letrozole treatment is more effective in preventing the return of cancer and prolonging survival.</summary>
    <trialwebsite>www.breastcancertrials.org.au</trialwebsite>
    <publication>Badger HD, Hunter LM, Chirgwin J, Forbes JF,Â Lindsay DF, Laycock I, Dempsey A. Strategies for Participant Recruitment: The SOLE Initiative. COSA 2010; Poster 222.

Forbes JF, Boyle F, Wilcken N, Lindsay DF, Leong E. Clinical Trials Open for Participant Entry. COSA 2010; Poster 242.

Colleoni M for the SOLE Collaborative and International Breast Cancer Study Groups. The SOLE Trial: International Breast Cancer Study Group (IBCSG 35-07) and Breast International Group (BIG 1-07) Study of Letrozole Extension. SABCS 2011;Poster OT2-02-01.

Colleoni M, Luo W, Karlsson P, Chirgwin JH, Aebi SP, Jerusalem GHM, Neven P, Hitre E, Graas M-P, Simoncini E, Kamby C, Thompson AM, Loibl S, Gavila J, Kuroi K, Gnant M, Rabaglio-Poretti, Regan MM, Coates AS, Goldhirsch A. SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC). Journal of Clinical Oncology 2017; 35, (suppl; abstr 503) [oral abstract][ASCO].</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>Breast Cancer Trials formerly known as the Australia &amp; New Zealand Breast Cancer Trials Group.</publicnotes>
    <ethicscommitee>
      <ethicname>Hunter New England Health Service</ethicname>
      <ethicaddress />
      <ethicapprovaldate>26/08/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>28/04/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>14/04/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Launceston General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/05/2008</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/08/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>2/06/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Maroondah Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>2/06/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Institute</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/05/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>2/06/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St John of God Hospital, Subiaco</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>30/06/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>2/06/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>5/08/2008</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Waikato Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>5/08/2008</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Jacquie Chirgwin</name>
      <address>Maroondah Breast Clinic
Maroondah Hospital
20 Grey Street
RINGWOOD EAST VIC  3135</address>
      <phone>+61 (03) 9871-3582</phone>
      <fax />
      <email>enquiries@bctrials.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Corinna Beckmore</name>
      <address>BCT
PO Box 283
The Junction NSW 2291</address>
      <phone>+61 2 4925 5235</phone>
      <fax>+61 2 4925 3068</fax>
      <email>enquiries@bctrials.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Jacquie Chirgwin</name>
      <address>Maroondah Breast Clinic
Maroondah Hospital
20 Grey Street
RINGWOOD EAST VIC  3135</address>
      <phone>+61 (03) 9871-3582</phone>
      <fax />
      <email>enquiries@bctrials.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>